WORLDSymposium™ 2024
Feb 7, 2024 at 8:00 AM PST
Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)
Robert J. Hopkin, Cincinnati Children’s Hospital Medical Center
• Platform Presentation: Wednesday, February 7, 2024 – 8:00am PT
• Poster Session: Wednesday, February 7, 2024 – 3-5pm PT (Poster: 145)
A 3-month gene therapy single-dose IV administration pharmacology and safety study with ST-920 (isaralgagene civaparvovec) for Fabry disease in mice
Kathleen E. Meyer, Sangamo Therapeutics
• Platform Presentation: Thursday, February 8, 2024 – 8:00am PT
• Poster Session: Thursday, February 8, 2024 – 3-5pm PT (Poster: 224)
Anti-AAV6 antibody assay for patient enrollment supporting ST-920 phase 1/2 study for Fabry disease
Liching Cao, Sangamo Therapeutics
• Poster Session: Thursday, February 8, 2024 – 3-5pm PT (Poster: 048)